Elanco Animal Health Inc
ELAN22.305USD
+0.215+0.97%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
11.08BMarket Cap
308.38P/E TTM
More Details of Elanco Animal Health Inc Company
Elanco Animal Health Incorporated is an animal health company delivering products and services to prevent and treat disease in farm animals and pets. The Company's product portfolio is sold in more than 90 countries and serves animals across many species, primarily dogs and cats (collectively, pet health) and cattle, poultry, swine, and sheep (collectively, farm animal). It has a diverse portfolio of products marketed under approximately 200 brands, including products for both pets and farm animals. The Company's global pet health portfolio is focused on parasiticides, vaccines and therapeutics. Its pet health products include Advantage Family, Atopica, Credelio Family, Drontal Family, Galliprant, Interceptor Plus, Milbemax, Onsior, Seresto, Trifexis, and TruCan. Its farm animal products include AviPro, Baytril, Catosal, Denagard, Experior, Hemicell, Maxiban/Monteban, Pulmotil, Rumensin, and Surmax. Its customers include consultants, veterinarians, farm animal producers and resellers.
Elanco Animal Health Inc Info
Ticker SymbolELAN
Company nameElanco Animal Health Inc
IPO dateSep 20, 2018
CEOSimmons (Jeffrey N)
Number of employees9000
Security typeOrdinary Share
Fiscal year-endSep 20
Address450 Elanco Circle
CityINDIANAPOLIS
Stock exchangeNASDAQ OMX NASDAQ Basic NYSE
CountryUnited States of America
Postal code46221
Phone18773526261
Websitehttps://www.elanco.com/
Ticker SymbolELAN
IPO dateSep 20, 2018
CEOSimmons (Jeffrey N)
Company Executives of Elanco Animal Health Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Jeffrey N. (Jeff) Simmons
Mr. Jeffrey N. (Jeff) Simmons
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.36M
+36.70%
Mr. David Kinard
Mr. David Kinard
Executive Vice President - Human Resources, Corporate Communications and Administration
Executive Vice President - Human Resources, Corporate Communications and Administration
205.68K
+7.83%
Mr. Lawrence Erik Kurzius
Mr. Lawrence Erik Kurzius
Independent Chairman of the Board
Independent Chairman of the Board
160.34K
+6.87%
Mr. Michael J. Harrington
Mr. Michael J. Harrington
Independent Director
Independent Director
109.58K
+10.39%
Mr. Art A. Garcia, CPA
Mr. Art A. Garcia, CPA
Independent Director
Independent Director
91.28K
+12.74%
Dr. Deborah Turner Kochevar, Ph.D.
Dr. Deborah Turner Kochevar, Ph.D.
Independent Director
Independent Director
89.71K
+12.99%
Mr. Paul S. Herendeen
Mr. Paul S. Herendeen
Independent Director
Independent Director
84.81K
+13.84%
Mr. Timothy J. (Tim) Bettington
Mr. Timothy J. (Tim) Bettington
Executive Vice President - Corporate Strategy and Market Development
Executive Vice President - Corporate Strategy and Market Development
80.40K
-22.66%
Mr. James Meer
Mr. James Meer
Senior Vice President, Chief Accounting Officer
Senior Vice President, Chief Accounting Officer
62.55K
-1.82%
Ms. Shiv O'Neill
Ms. Shiv O'Neill
Executive Vice President, General Counsel, Corporate Secretary
Executive Vice President, General Counsel, Corporate Secretary
53.92K
+100.82%
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Jeffrey N. (Jeff) Simmons
Mr. Jeffrey N. (Jeff) Simmons
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.36M
+36.70%
Mr. David Kinard
Mr. David Kinard
Executive Vice President - Human Resources, Corporate Communications and Administration
Executive Vice President - Human Resources, Corporate Communications and Administration
205.68K
+7.83%
Mr. Lawrence Erik Kurzius
Mr. Lawrence Erik Kurzius
Independent Chairman of the Board
Independent Chairman of the Board
160.34K
+6.87%
Mr. Michael J. Harrington
Mr. Michael J. Harrington
Independent Director
Independent Director
109.58K
+10.39%
Mr. Art A. Garcia, CPA
Mr. Art A. Garcia, CPA
Independent Director
Independent Director
91.28K
+12.74%
Dr. Deborah Turner Kochevar, Ph.D.
Dr. Deborah Turner Kochevar, Ph.D.
Independent Director
Independent Director
89.71K
+12.99%
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
By BusinessUSD
Name
Revenue
Proportion
Pet Health
643.00M
51.81%
Farm Animal
583.00M
46.98%
Contract Manufacturing
15.00M
1.21%
By RegionUSD
Name
Revenue
Proportion
International
648.00M
52.22%
United States
593.00M
47.78%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Pet Health
643.00M
51.81%
Farm Animal
583.00M
46.98%
Contract Manufacturing
15.00M
1.21%
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Dodge & Cox
16.66%
Fidelity Management & Research Company LLC
10.21%
PRIMECAP Management Company
10.05%
The Vanguard Group, Inc.
9.75%
BlackRock Institutional Trust Company, N.A.
8.13%
Other
45.19%
Shareholders
Shareholders
Proportion
Dodge & Cox
16.66%
Fidelity Management & Research Company LLC
10.21%
PRIMECAP Management Company
10.05%
The Vanguard Group, Inc.
9.75%
BlackRock Institutional Trust Company, N.A.
8.13%
Other
45.19%
Shareholder Types
Shareholders
Proportion
Investment Advisor
70.39%
Investment Advisor/Hedge Fund
36.66%
Hedge Fund
5.79%
Research Firm
1.90%
Individual Investor
1.13%
Pension Fund
1.08%
Bank and Trust
0.65%
Sovereign Wealth Fund
0.18%
Family Office
0.11%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
852
577.24M
120.43%
+30.91K
2025Q3
891
577.57M
121.95%
+32.95M
2025Q2
878
543.55M
113.98%
+36.20M
2025Q1
945
503.90M
116.31%
-73.53M
2024Q4
964
498.16M
117.36%
+7.74M
2024Q3
970
490.73M
118.81%
+19.54K
2024Q2
1004
491.01M
118.24%
+1.27M
2024Q1
1021
489.85M
119.72%
-100.34M
2023Q4
1018
489.74M
120.73%
-3.72M
2023Q3
1027
490.57M
119.00%
+3.49M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Dodge & Cox
82.90M
16.69%
-25.35K
-0.03%
Jun 30, 2025
Fidelity Management & Research Company LLC
48.24M
9.71%
+9.93M
+25.93%
Jun 30, 2025
PRIMECAP Management Company
51.77M
10.42%
+1.54M
+3.07%
Jun 30, 2025
The Vanguard Group, Inc.
47.65M
9.59%
-496.16K
-1.03%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
19.58M
3.94%
-484.75K
-2.42%
Jun 30, 2025
T. Rowe Price Investment Management, Inc.
19.55M
3.94%
+3.57M
+22.35%
Jun 30, 2025
Dimensional Fund Advisors, L.P.
22.75M
4.58%
+2.28M
+11.15%
Jun 30, 2025
UBS Financial Services, Inc.
10.31M
2.08%
+5.99M
+138.56%
Jun 30, 2025
State Street Investment Management (US)
9.13M
1.84%
-125.36K
-1.35%
Jun 30, 2025
Fidelity Institutional Asset Management
16.64M
3.35%
+1.09M
+7.01%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares U.S. Pharmaceuticals ETF
4.06%
Adaptiv Select ETF
3.38%
State Street SPDR S&P Pharmaceuticals ETF
3.15%
Brandes US Small-Mid Cap Value ETF
3.14%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
2.84%
VanEck Agribusiness ETF
2.3%
First Trust Health Care Alphadex Fund
1.92%
Federated Hermes MDT Large Cap Value ETF
1.9%
First Trust NASDAQ Pharmaceuticals ETF
1.33%
Invesco S&P MidCap 400 Pure Value ETF
1.22%
View more
iShares U.S. Pharmaceuticals ETF
Proportion4.06%
Adaptiv Select ETF
Proportion3.38%
State Street SPDR S&P Pharmaceuticals ETF
Proportion3.15%
Brandes US Small-Mid Cap Value ETF
Proportion3.14%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proportion2.84%
VanEck Agribusiness ETF
Proportion2.3%
First Trust Health Care Alphadex Fund
Proportion1.92%
Federated Hermes MDT Large Cap Value ETF
Proportion1.9%
First Trust NASDAQ Pharmaceuticals ETF
Proportion1.33%
Invesco S&P MidCap 400 Pure Value ETF
Proportion1.22%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Elanco Animal Health Inc?
The top five shareholders of Elanco Animal Health Inc are:
Dodge & Cox holds 82.90M shares, accounting for 16.69% of the total shares.
Fidelity Management & Research Company LLC holds 48.24M shares, accounting for 9.71% of the total shares.
PRIMECAP Management Company holds 51.77M shares, accounting for 10.42% of the total shares.
The Vanguard Group, Inc. holds 47.65M shares, accounting for 9.59% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 19.58M shares, accounting for 3.94% of the total shares.
Dodge & Cox holds 82.90M shares, accounting for 16.69% of the total shares.
Fidelity Management & Research Company LLC holds 48.24M shares, accounting for 9.71% of the total shares.
PRIMECAP Management Company holds 51.77M shares, accounting for 10.42% of the total shares.
The Vanguard Group, Inc. holds 47.65M shares, accounting for 9.59% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 19.58M shares, accounting for 3.94% of the total shares.
What are the top three shareholder types of Elanco Animal Health Inc?
The top three shareholder types of Elanco Animal Health Inc are:
Dodge & Cox
Fidelity Management & Research Company LLC
PRIMECAP Management Company
Dodge & Cox
Fidelity Management & Research Company LLC
PRIMECAP Management Company
How many institutions hold shares of Elanco Animal Health Inc (ELAN)?
As of 2025Q4, 852 institutions hold shares of Elanco Animal Health Inc, with a combined market value of approximately 577.24M, accounting for 120.43% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -1.52%.
What is the biggest source of revenue for Elanco Animal Health Inc?
In FY2025Q2, the Pet Health business generated the highest revenue for Elanco Animal Health Inc, amounting to 643.00M and accounting for 51.81% of total revenue.
